Demographic and clinical characteristics of patients
| . | No NAFLD (n = 51) . | NAFLD . | P value . | |
|---|---|---|---|---|
| No NASH (n = 72) . | Definite NASH (n = 90) . | |||
| Age, years | 60 ± 8 | 57 ± 9 | 57 ± 8 | 0.08 |
| Sex, male % | 86 | 82 | 83 | 0.81 |
| Ethnicity, n (%) | ||||
| Caucasian | 32 (63) | 38 (53) | 58 (65) | |
| Hispanic | 8 (16) | 27 (37) | 27 (30) | 0.011 |
| African American | 11 (21) | 7 (10) | 4 (4) | |
| Other | 0 (0) | 0 (0) | 1 (1) | |
| BMI, kg/m2 | 31.2 ± 4.5 | 34.2 ± 4.7 | 34.7 ± 4.7 | <0.001 |
| Total body fat, % | 34 ± 6 | 36 ± 7 | 36 ± 7 | 0.17 |
| Hemoglobin A1c, % | 7.1 ± 1.3 | 6.9 ± 1.1 | 7.2 ± 1.2 | 0.31 |
| Fasting plasma glucose, mg/mL | 150 ± 50 | 137 ± 36 | 153 ± 42 | 0.06 |
| Fasting plasma insulin, μU/mL | 8 ± 6 | 14 ± 10 | 19 ± 13 | <0.001 |
| Diabetes medications, % | ||||
| Metformin | 75 | 67 | 79 | 0.25 |
| Sulfonylurea | 44 | 44 | 38 | 0.73 |
| Insulin | 29 | 31 | 18 | 0.12 |
| Intrahepatic triglyceride content, % | 3 ± 1 | 12 ± 7 | 15 ± 8 | <0.001 |
| AST, units/L | 22 ± 7 | 32 ± 18 | 48 ± 29 | <0.001 |
| ALT, units/L | 24 ± 11 | 43 ± 33 | 64 ± 41 | <0.001 |
| NAFLD activity score | — | 2.3 ± 0.9 | 4.8 ± 1.3 | <0.001 |
| Steatosis grade | — | 1.2 ± 0.8 | 1.9 ± 0.7 | <0.001 |
| Inflammation grade | — | 1.0 ± 0.5 | 1.6 ± 0.6 | <0.001 |
| Ballooning grade | — | 0.1 ± 0.3 | 1.3 ± 0.5 | <0.001 |
| Fibrosis stage | — | 0.6 ± 0.9 | 1.8 ± 1.0 | <0.001 |
| . | No NAFLD (n = 51) . | NAFLD . | P value . | |
|---|---|---|---|---|
| No NASH (n = 72) . | Definite NASH (n = 90) . | |||
| Age, years | 60 ± 8 | 57 ± 9 | 57 ± 8 | 0.08 |
| Sex, male % | 86 | 82 | 83 | 0.81 |
| Ethnicity, n (%) | ||||
| Caucasian | 32 (63) | 38 (53) | 58 (65) | |
| Hispanic | 8 (16) | 27 (37) | 27 (30) | 0.011 |
| African American | 11 (21) | 7 (10) | 4 (4) | |
| Other | 0 (0) | 0 (0) | 1 (1) | |
| BMI, kg/m2 | 31.2 ± 4.5 | 34.2 ± 4.7 | 34.7 ± 4.7 | <0.001 |
| Total body fat, % | 34 ± 6 | 36 ± 7 | 36 ± 7 | 0.17 |
| Hemoglobin A1c, % | 7.1 ± 1.3 | 6.9 ± 1.1 | 7.2 ± 1.2 | 0.31 |
| Fasting plasma glucose, mg/mL | 150 ± 50 | 137 ± 36 | 153 ± 42 | 0.06 |
| Fasting plasma insulin, μU/mL | 8 ± 6 | 14 ± 10 | 19 ± 13 | <0.001 |
| Diabetes medications, % | ||||
| Metformin | 75 | 67 | 79 | 0.25 |
| Sulfonylurea | 44 | 44 | 38 | 0.73 |
| Insulin | 29 | 31 | 18 | 0.12 |
| Intrahepatic triglyceride content, % | 3 ± 1 | 12 ± 7 | 15 ± 8 | <0.001 |
| AST, units/L | 22 ± 7 | 32 ± 18 | 48 ± 29 | <0.001 |
| ALT, units/L | 24 ± 11 | 43 ± 33 | 64 ± 41 | <0.001 |
| NAFLD activity score | — | 2.3 ± 0.9 | 4.8 ± 1.3 | <0.001 |
| Steatosis grade | — | 1.2 ± 0.8 | 1.9 ± 0.7 | <0.001 |
| Inflammation grade | — | 1.0 ± 0.5 | 1.6 ± 0.6 | <0.001 |
| Ballooning grade | — | 0.1 ± 0.3 | 1.3 ± 0.5 | <0.001 |
| Fibrosis stage | — | 0.6 ± 0.9 | 1.8 ± 1.0 | <0.001 |
Data are mean ± SD unless otherwise indicated. P values represent comparison among the three groups with ANOVA.